OClawVPS.com
Senda Biosciences
Edit

Senda Biosciences

https://www.sendabiosciences.com/
Last activity: 22.08.2022
Active
Categories: BioTechHealthTechHumanITLifePlatform
Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda’s proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.
Followers
205
Mentions
9
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $221M
Founded date: 2017

Investors 2

Funding Rounds 2

DateSeriesAmountInvestors
31.08.2022Series C$123M-
11.06.2021Series B$98M-

Mentions in press and media 9

DateTitleDescription
22.08.2022Senda Biosciences Raised $123M, ThreatX Got $30M, and More Boston Tech NewsPhoto: ThreatX / LinkedIn There was no shortage of funding news in the Boston tech scene last week. Venture dollars poured into a wide range of companies in biotech, cybersecurity and more. Read on to see who’s hiring and find out how these...
16.08.2022Senda Biosciences Closes $123M Series C FinancingSenda Biosciences, a Cambridge, MA-based company that leverages nature to program targeted, potent, and tunable medicines, raised $123M in Series C funding. The round was led by Flagship Pioneering, with participation from Samsung Life Scie...
16.08.2022Senda Biosciences Completes $123M Series C CAMBRIDGE, MA, Senda Biosciences today announced the completion of a $123 million Series C financing. >> Click here for more funding data on Senda Biosciences >> To export Senda Biosciences funding data to PDF and Excel, cli...
26.01.2022Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform BiologyCAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vi...
11.06.2021Senda Biosciences Closes $98M Series B FinancingSenda Biosciences, a Cambridge, Mass.-based company that harnesses the molecular interactions between humans, plants, and bacteria to develop new types of medicines, raised a $55m Series B extension financing, bringing its total Series B fu...
10.06.2021Senda Biosciences Announces Closing of $98 Million Series B Financing
10.06.2021Senda Biosciences : Announces Closing of $98 Million Series B FinancingCAMBRIDGE, Mass., June 10, 2021 /PRNewswire/ -- Senda Biosciences, a company that is systematically harnessing the powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of...
07.01.2021Senda Biosciences Announces Formation of World-Class Scientific Advisory Board
-13 самых больших инвестиций неделиГлавное на 2.3 миллиарда долларов. Обзор самых крупных инвестиционных раундов прошедшей недели в мире. Авиасейлз для богатых, Убер для очень богатых, программируемые лекарства, творческий маркетинг и многое другое. 0 Обсудить 55 просмотров ...

Reviews 0

Sign up to leave a review

Sign up Log In